Total Payments
$108,809
2024 Payments
$4,163
Companies
5
Transactions
42
Payment Breakdown by Category
Research$63,700 (58.5%)
Consulting$31,585 (29.0%)
Travel$10,737 (9.9%)
Other$2,500 (2.3%)
Food & Beverage$286.49 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $63,700 | 20 | 58.5% |
| Consulting Fee | $31,585 | 9 | 29.0% |
| Travel and Lodging | $10,737 | 7 | 9.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,500 | 1 | 2.3% |
| Food and Beverage | $286.49 | 5 | 0.3% |
Payments by Type
Research
$63,700
20 transactions
General
$45,109
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $70,670 | 23 | $0 (2024) |
| Novartis Pharma AG | $19,951 | 7 | $0 (2018) |
| Daiichi Sankyo Inc. | $9,342 | 8 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $6,345 | 3 | $0 (2021) |
| BIOTRONIK INC. | $2,500 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,163 | 1 | Celgene Corporation ($4,163) |
| 2023 | $12,193 | 5 | Celgene Corporation ($12,193) |
| 2022 | $11,688 | 3 | Celgene Corporation ($11,688) |
| 2021 | $17,455 | 5 | Celgene Corporation ($14,350) |
| 2020 | $18,980 | 7 | Celgene Corporation ($15,740) |
| 2019 | $14,017 | 9 | Daiichi Sankyo Inc. ($9,342) |
| 2018 | $14,442 | 5 | Novartis Pharma AG ($10,080) |
| 2017 | $15,872 | 7 | Novartis Pharma AG ($9,872) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $4,162.50 | Research |
| Study: Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease • Category: Neuroscience | ||||||
| 08/18/2023 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $4,162.50 | Research |
| Study: PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) • Category: Neuroscience | ||||||
| 06/16/2023 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $2,782.50 | Research |
| Study: To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis • Category: Neuroscience | ||||||
| 06/16/2023 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $2,220.00 | Research |
| Study: PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) • Category: Neuroscience | ||||||
| 03/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| Category: Neuroscience | ||||||
| 01/04/2023 | Celgene Corporation | — | — | Cash or cash equivalent | $530.00 | Research |
| Study: Ph II / III Pediatric CD study | ||||||
| 12/20/2022 | Celgene Corporation | — | — | Cash or cash equivalent | $1,060.00 | Research |
| Study: A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy | ||||||
| 06/02/2022 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $3,710.00 | Research |
| Study: To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis • Category: Neuroscience | ||||||
| 02/17/2022 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $6,917.50 | Research |
| Study: Induction Study #2 - A Phase 3, Multicenter, Rando • Category: Neuroscience | ||||||
| 12/22/2021 | Celgene Corporation | — | — | Cash or cash equivalent | $2,385.00 | Research |
| Study: A Study of RCP01 in Patients with Relapsed or Refractory Multiple Myeloma | ||||||
| 06/17/2021 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $2,252.50 | General |
| 05/21/2021 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Neuroscience | ||||||
| 02/26/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,105.00 | General |
| 02/04/2021 | Celgene Corporation | ZEPOSIA (Drug) | — | Cash or cash equivalent | $7,492.50 | Research |
| Study: Induction Study #2 - A Phase 3, Multicenter, Rando • Category: Neuroscience | ||||||
| 12/10/2020 | Celgene Corporation | — | — | Cash or cash equivalent | $2,120.00 | Research |
| Study: To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | ||||||
| 10/20/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| 06/15/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| 06/04/2020 | Celgene Corporation | Pomalyst (Drug) | — | Cash or cash equivalent | $2,385.00 | Research |
| Study: Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma • Category: Hematology | ||||||
| 05/18/2020 | Celgene Corporation | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: (RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) | ||||||
| 03/18/2020 | Celgene Corporation | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) | ||||||
| 03/05/2020 | Celgene Corporation | — | — | Cash or cash equivalent | $9,135.00 | Research |
| Study: PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) | ||||||
| 06/19/2019 | Celgene Corporation | RPC-1063 (Drug) | — | Cash or cash equivalent | $4,675.00 | Research |
| Study: PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) | ||||||
| 04/18/2019 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $8,250.00 | General |
| 03/05/2019 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $63.47 | General |
| 03/05/2019 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $33.06 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Induction Study #2 - A Phase 3, Multicenter, Rando | Celgene Corporation | $14,410 | 2 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) | Celgene Corporation | $9,135 | 1 |
| To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | Celgene Corporation | $8,613 | 3 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) | Celgene Corporation | $6,383 | 2 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) | Celgene Corporation | $4,675 | 1 |
| Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Celgene Corporation | $4,163 | 1 |
| RPC01-3202 - PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) | Celgene Corporation | $2,613 | 1 |
| A Study of RCP01 in Patients with Relapsed or Refractory Multiple Myeloma | Celgene Corporation | $2,385 | 1 |
| Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $2,385 | 1 |
| RPC01-3101 | Celgene Corporation | $1,750 | 1 |
| RPC01-3102 | Celgene Corporation | $1,750 | 1 |
| RPC01-3102 - PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) | Celgene Corporation | $1,750 | 1 |
| (RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) | Celgene Corporation | $1,400 | 1 |
| A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy | Celgene Corporation | $1,060 | 1 |
| PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) | Celgene Corporation | $700.00 | 1 |
| Ph II / III Pediatric CD study | Celgene Corporation | $530.00 | 1 |
About Dr. John Dimarco, M.D
Dr. John Dimarco, M.D is a Cardiovascular Disease healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548324395.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Dimarco, M.D has received a total of $108,809 in payments from pharmaceutical and medical device companies, with $4,163 received in 2024. These payments were reported across 42 transactions from 5 companies. The most common payment nature is "" ($63,700).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Clinical Cardiac Electrophysiology
- Location Charlottesville, VA
- Active Since 12/19/2006
- Last Updated 09/12/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1548324395
Products in Payments
- ZEPOSIA (Drug) $36,165
- Gilenya (Drug) $9,872
- FTY (Drug) $7,920
- RPC-1063 (Drug) $4,675
- Ozanimod (Drug) $4,363
- RPC1063 (Drug) $3,500
- Pomalyst (Drug) $2,385
- FTY720D (Drug) $2,160
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Charlottesville
Dr. Todd Villines, M.d, M.D
Cardiovascular Disease — Payments: $359,051
Cardiovascular Disease $359,051
David Lim
Cardiovascular Disease — Payments: $284,770
Cardiovascular Disease $284,770
Christopher Kramer, Md, MD
Cardiovascular Disease — Payments: $196,022
Cardiovascular Disease $196,022
Dr. Antonio Abbate, M.d, M.D
Cardiovascular Disease — Payments: $185,293
Cardiovascular Disease $185,293
Dr. Michael Ayers, M.d, M.D
Cardiovascular Disease — Payments: $172,824
Cardiovascular Disease $172,824
Pamela Mason, M.d, M.D
Cardiovascular Disease — Payments: $90,849
Cardiovascular Disease $90,849